Vast’s Lead Drug Candidate Receives Orphan Drug Designation for Treatment of Respiratory Infection for Cystic Fibrosis
Phase 1 program set to begin Q4 2025 in the US MORRISVILLE, NC, UNITED STATES, July 16, 2025 /EINPresswire.com/ -- Vast Therapeutics, a clinical-stage life science company, today announced that the U.S. Food and Drug Administration (FDA) has granted …